TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04969887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
Study: NCT04220125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Group
Description: Ketamine intravenous administration 0.5 mg/kg over 40 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: Midazolam intravenous administration 0.045 mg/kg IV over 40 minutes.
Study: NCT05151315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty with Evolution® NitrX™ Knee System
Description: Patients will receive cemented Evolution knee system with NitrX coating for their total knee arthroplasty.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty with Evolution Knee System
Description: Patients will receive cemented Evolution knee system without NitrX coating for their total knee arthroplasty.
Study: NCT05512156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Toothbrushing
Description: * Recruitment, consent, and Questionnaires (Behaviors, Quality of Live, Cost Analysis) distribution.~* Inclusion \& Exclusion Criteria Applied~* Baseline Dental examination~* Toothbrushes \& Toothpastes Home and school use packs delivery-Colgate (six pack per child a year- child soft toothbrush with a1450ppm fluoridated toothpaste))~* Supervised teachers training~* Three months intervals monitoring visits~* 12months Follow up and Questionnaires (Behaviours) distribution~* Endpoint dental Examination and Questionnaires (Behaviours, Quality of Live, Cost Analysis) distribution
Study: NCT04496713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-connected computer tablet
Description: An internet-connected tablet provided to patient for upcoming visit with physician by audio/video which can also be used to complete a survey.
Study: NCT06141525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: An automatic programmed blood pressure cuffs will be placed on two upper limbs of the patient and pressurized to 200 mmHg (or at least 20 mmHg higher than the systolic blood pressure if the systolic blood pressure of the patient is above 180 mmHg) with 5 minutes of pressurization and 5 minutes of rest. One pressurization with rest is deemed as one cycle (10 minutes), and 4 cycles will be performed each time (for a total of 40 minutes).
Study: NCT05055986

Intervention type: DEVICE
Intervention: Semiautomatic segmentation of open-source software
Description: Semiautomatic segmentation of open-source software is accurate as of the manual segmentation of commercial software.
Study: NCT06459323

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study: NCT05171439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Study: NCT05467878

Intervention type: OTHER
Intervention: The anesthesia and analgesia technique preferred by the anesthetist will be recorded.
Description: In the study, the anesthesia method applied by blind anesthesiologists in the peroperative period, the drugs or techniques used for analgesia will be recorded and their effects on the postoperative period and hospital stay will be examined.There will be no intervention in the perioperative and postoperative process.

Intervention type: OTHER
Intervention: The anesthesia and analgesia technique preferred by the anesthetist will be recorded.
Description: In the study, the anesthesia method applied by blind anesthesiologists in the peroperative period, the drugs or techniques used for analgesia will be recorded and their effects on the postoperative period and hospital stay will be examined.There will be no intervention in the perioperative and postoperative process.

Intervention type: OTHER
Intervention: The anesthesia and analgesia technique preferred by the anesthetist will be recorded.
Description: In the study, the anesthesia method applied by blind anesthesiologists in the peroperative period, the drugs or techniques used for analgesia will be recorded and their effects on the postoperative period and hospital stay will be examined.There will be no intervention in the perioperative and postoperative process.
Study: NCT06305000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Description: Non-surgical treatment consists of oral hygiene instructions, full mouth supragingival scaling using titanium hand instruments, ultrasonic devices, and subgingival debridement under local anesthesia with titanium curettes and ultrasonic instruments in a single appointment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Description: Non-surgical treatment consists of oral hygiene instructions, full mouth supragingival scaling using titanium hand instruments, ultrasonic devices, and subgingival debridement under local anesthesia with titanium curettes and ultrasonic instruments in a single appointment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Description: Non-surgical treatment consists of oral hygiene instructions, full mouth supragingival scaling using titanium hand instruments, ultrasonic devices, and subgingival debridement under local anesthesia with titanium curettes and ultrasonic instruments in a single appointment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: After adequate local anesthesia is achieved. A horizontal incision is placed mucogingival junction level to prepare the recipient bed. A split-thickness flap is raised without disturbing the periosteum. FGG is obtained from the palate, extending from the mesial surface of the second premolar to the middle of the first molar. The graft is shaped and stitched on the recipient surface.
Study: NCT04263285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The study team will deliver rTMS five days a week for four weeks, according to a specific and approved protocol for participant positioning, motor threshold determination, and dosing.
Study: NCT06112808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-263
Description: BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opdivo
Description: Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
Study: NCT06440616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectral CT images generated by a photon counting CT scanner
Description: The reading radiologist will in the experimental arm have access to spectral CT images in the form of low virtual monoenergetic images, virtual non-contrast images, iodine maps and effective atomic number. In the non-interventional arms the reading radiologist will only have access to conventional CT images.
Study: NCT05902247

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radionuclide Therapy
Description: To evaluate the tolerability and safety of 225Ac-PSMA I\&T in patients with metastatic prostate cancer
Study: NCT05722704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Final irrigation with cold saline (2.5C-4C) without occlusal reduction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal reduction
Description: Reduction of the functional and non-functional cusps
Study: NCT05786443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Sodium glucose cotransporter 2 inhibitor (SGLT2i) dosed once-daily over 12 weeks. Administered as oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empagliflozin-matching placebo dosed once-daily over 12 weeks. Administered as oral tablet.
Study: NCT05627713

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection
Description: Blood sample collection between inclusion and 12 months after inclusion

Intervention type: OTHER
Group type: OTHER
Intervention: urine sample collection
Description: urine sample collection at inclusion
Study: NCT05181865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg/kg IV FL-301
Description: N = 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg/kg IV FL-301
Description: N = 3-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg IV FL-301
Description: N = 3-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg/kg IV FL-301
Description: N = 3-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg/kg IV FL-301
Description: N = 3-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP2D, IV FL-301
Description: Pancreatic Cancer N = 30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP2D, IV FL-301
Description: Gastric Cancer (Including GEJ) N = 30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP2D, IV FL-301
Description: Other Solid Tumors N = 30
Study: NCT06206369

Intervention type: OTHER
Intervention: No intervention, retrospective study
Description: No intervention, retrospective study

Intervention type: OTHER
Intervention: No intervention, retrospective study
Description: No intervention, retrospective study
Study: NCT06008886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: Normocaloric diet based solely on foods of plant sources.
Study: NCT02864784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amorphous calcium carbonate
Description: Subjects in this arm of the study will receive standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab) as well as AMOR-1 tablets, containing 200 mg elemental calcium per tablet, individually titrated up to the maximum level which does not induce grade 2 hypercalcemia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose
Study: NCT06008886

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Diet with a predominance of plant foods fruits, vegetables, whole grains, nuts and legumes); moderate to low consumption of fish, white meat, low-fat dairy and eggs; and very low consumption of red and processed meats, butter, full-fat dairy and sweets.
Study: NCT05744271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES+VFBT
Description: Standing balance training with the FES+VFBT system will occur 3x/week for six weeks (i.e. 18 sessions). Electrodes will be placed on the participants' plantarflexors and dorsiflexors bilaterally and FES will be administered using the device, MyndSearch, during the balance training exercises. Each session will last one hour, including 15 min to identify motor thresholds and maximum tolerable stimulation levels, 5 min to don/doff the safety harness, 5 min to calibrate the FES+VFBT exercises, 20 min to complete the FES+VFBT exercises, and 10-15 min to take rest breaks between exercises as needed.
Study: NCT05628116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC243 50 mg single
Description: The volunteers will receive a single dose of the ID (1 tablet once, 50 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC243 100 mg single
Description: The volunteers will receive a single dose of the ID (2 tablets once, 100 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single
Description: The volunteers will receive a single dose of the ID (1 or 2 tablets once)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC243 200 mg single-dose food effect
Description: The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets, 200 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single-dose food effect
Description: The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC243 200 mg multiple
Description: The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily, 200 mg each)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple
Description: The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily)
Study: NCT04286568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WOW Intervention
Description: Health education and coaching, health care navigation,
Study: NCT04264078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 UCAR-T cells
Description: Dose range:1 to 5 ×10\^7 cells/Kg, Dose level one: 1×10\^7 cells/Kg, Dose level two: 3×10\^7 cells/Kg, Dose level three:5 ×10\^7 cells/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m\^2 per day for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 600mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
Study: NCT04687670

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ERA
Description: Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the ERA test will be provided to participants and their gynecologists for the personalized embryo transfer.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ERA
Description: Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
Study: NCT05614895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7223280
Description: Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7223280
Description: Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7223280
Description: Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7223280
Description: Participants will receive RO7223280, 400 mg, IV infusion for 1 hour on Day 1.
Study: NCT06279065

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of blood and microbiome samples (stool, oral lavage)
Description: Analysis of blood and microbiome samples (stool, oral lavage) especially composition of the gut microbiome and potential interaction with immune cells

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of blood and microbiome samples (stool, oral lavage)
Description: Analysis of blood and microbiome samples (stool, oral lavage) especially composition of the gut microbiome and potential interaction with immune cells
Study: NCT06516900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoFeet HandsFree Therapeutic Shoe
Description: Patients with foot pain will be recruited for this study and will go for an intervention of wearing OrthoFeet therapeutic shoes for 6 weeks. Each patient will be evaluated and will participate in data collection before and after intervention.
Study: NCT04756960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001
Description: 4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of \[14\^C\]-labelled CHF6001
Study: NCT05625594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration
Description: Undergo CSF aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheterization
Description: Undergo catheterization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes
Description: Given ICV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT06311604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Inclusions will have 4 phases according to gradual increased doses of isoflurane:~Phase 1: Inclusion of 3 patients with 0.3 MAC isoflurane. In the absence of an increase of ICP \> 20% from baseline, inhaled sedation is maintained for 24 hours until the primary endpoint is assessed. If there one patient who does not tolerate this threshold, three additional patients will be included in this phase. A maximum of one treatment failure (see definition below) is tolerated in the phase 1~Phase 2: Inclusion of 3 additional patients with isoflurane dosage of 0.5 MAC under the same conditions as phase 1.~Phase 3: Inclusion of 3 additional patients with isoflurane dosage of 0.7 MAC under the same conditions as phases 1 and 2.~Phase 4: Inclusion of 12-15 additional patients will be included at the 0.7 MAC dose, to have 18 patients exposed to 0.7 MAC isoflurane.
Study: NCT04540848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A (Exparel plus supraclavicular block)
Description: Patients will receive 20 cc (266 mg) of Exparel injected in the distal radius area and a supraclavicular block in the recovery room.The supraclavicular blocks will be ultrasound guided and consist of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B (Bupivacaine HCL plus supraclavicular block)
Description: Patients will receive 20 cc of Bupivacaine 0.25% (50mg) in the distal radius area.In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group C(supraclavicular block only)
Description: In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket.
Study: NCT04578574

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bodily Illusions (BI) Procedure
Description: Each sessions will consists of two types of illusions that are 15 min each, the rubber hand illusion (RHI) and the walking illusion (WI) that involve both arms and legs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bodily Illusions (BI) Procedure
Description: Each sessions will consists of two types of illusions that are 15 min each, the rubber hand illusion (RHI) and the walking illusion (WI) that involve both arms and legs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct electrical stimulation (tDCS)
Description: Each sessions will consists of electrical current delivered from a battery-driven, constant current stimulator using saline-soaked surface sponge electrodes. One electrode will be placed on your scalp on the right side and the other electrode over the left eye on your forehead. A weak current will be applied for 30 min at the same time as the BI.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Electrical Stimulation (tDCS)
Description: Each session of the Sham tDCS will be applied for 30 min at the same time as the BI.